Duration of protection by oxitropium bromide against cholinergic challenge

Eur J Respir Dis. 1987 Nov;71(5):455-8.

Abstract

In order to determine the duration of action of the inhaled anticholinergic agent oxitropium bromide, a controlled study of the effect of pre-treatment with oxitropium bromide 200 micrograms against cholinergic challenge was carried out in ten asthmatic subjects (6 children, 4 adults). After baseline measurements of lung function (FEV1 and sGaw) and methacholine PC20 (the concentration of methacholine to produce a 20% fall in FEV1) oxitropium bromide or placebo were inhaled double-blind on 2 separate days. Lung function and methacholine PC20 were then measured at 1, 3 and 6 h post dosing. Oxitropium bromide caused significant protection from methacholine challenge for 6 h (p less than 0.05).

Publication types

  • Clinical Trial
  • Controlled Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Asthma / drug therapy*
  • Asthma / physiopathology
  • Bronchi / drug effects
  • Child
  • Female
  • Forced Expiratory Volume
  • Humans
  • Male
  • Methacholine Chloride
  • Methacholine Compounds / pharmacology
  • Middle Aged
  • Parasympatholytics / pharmacology
  • Parasympatholytics / therapeutic use*
  • Parasympathomimetics / pharmacology
  • Respiratory Function Tests
  • Scopolamine Derivatives / pharmacology
  • Scopolamine Derivatives / therapeutic use*

Substances

  • Methacholine Compounds
  • Parasympatholytics
  • Parasympathomimetics
  • Scopolamine Derivatives
  • Methacholine Chloride
  • oxitropium